Clinical features and comorbidities associated with migraine in bipolar disorder: Results from the FACE-BD cohort.
Journal of Affective Disorders. 2025-06-01; 379: 289-296
DOI: 10.1016/j.jad.2025.03.045
Lire sur PubMed
Samalin L(1), Godin O(2), Moisset X(3), Chalayer A(4), Pelletier A(2), Lefrere
A(5), Roux P(6), Polosan M(7), Bogdan A(8), Schwan R(9), Dubertret C(10),
Aouizerate B(11), Belzeaux R(12), Rey R(13), Januel D(14), Walter M(15), Yrondi
A(16), Haffen E(17), Courtet P(18), Bellivier F(19), Leboyer M(2); FACE-BD
collaborators; Etain B(19), Olié E(18), Llorca PM(4).
Author information:
(1)Fondation Fondamental, Créteil, France; University of Clermont Auvergne, CHU
Clermont-Ferrand, CNRS, IP, UMR 6602, Clermont-Ferrand, France. Electronic
address: .
(2)Fondation Fondamental, Créteil, France; Univ Paris Est Créteil, INSERM, IMRB,
Translational Neuro-Psychiatry, AP-HP, DMU IMPACT, FHU ADAPT, Psychiatry and
addictology of Mondor University Hospital, Créteil, France.
(3)University of Clermont Auvergne, CHU Clermont-Ferrand, Inserm, Neuro-Dol,
Clermont-Ferrand, France.
(4)Fondation Fondamental, Créteil, France; University of Clermont Auvergne, CHU
Clermont-Ferrand, CNRS, IP, UMR 6602, Clermont-Ferrand, France.
(5)Fondation Fondamental, Créteil, France; Pôle de Psychiatrie, Assistance
Publique Hôpitaux de Marseille, Marseille, France; Institut de Neurosciences de
la Timone, Aix-Marseille Univ, UMR CNRS, France.
(6)Fondation Fondamental, Créteil, France; Centre Hospitalier de Versailles,
Service Hospitalo-Universitaire de Psychiatrie d’Adultes et d’Addictologie, Le
Chesnay, MOODS team, INSERM UMR1018, CESP, Faculté de Médecine Paris-Saclay,
Université de Versailles Saint-Quentin-En-Yvelines, Université Paris-Saclay,
Villejuif, France.
(7)Fondation Fondamental, Créteil, France; Université Grenoble Alpes, Inserm,
U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Grenoble, France.
(8)Fondation Fondamental, Créteil, France; Pôle de Psychiatrie, Centre
Hospitalier Princesse Grace, Monaco.
(9)Fondation Fondamental, Créteil, France; Université de Lorraine, Centre
Psychothérapique de Nancy, Inserm U1254, Nancy, France.
(10)Fondation Fondamental, Créteil, France; AP-HP, Groupe
Hospitalo-Universitaire AP-HP Nord, DMU ESPRIT, Service de Psychiatrie et
Addictologie, Hôpital Louis Mourier, Colombes, France; Université de Paris,
Inserm UMR1266, Sorbonne Paris Cité, Faculté de Médecine, Paris, France.
(11)Fondation Fondamental, Créteil, France; Centre Hospitalier Charles Perrens,
Laboratoire NutriNeuro (UMR INRA 1286), Université de Bordeaux, Bordeaux,
France.
(12)Fondation Fondamental, Créteil, France; Department of Psychiatry, CHU
Montpellier; IGF, Université de Montpellier, CNRS, INSERM, Montpellier, France.
(13)Fondation Fondamental, Créteil, France; Bipolar Disorder Expert Centre, Le
Vinatier Hospital, Bron; University Lyon 1, Villeurbanne; INSERM, U1028; CNRS,
UMR5292; Lyon Neuroscience Research Center, Psychiatric Disorders, Neuroscience
Research and Clinical Research Team, Lyon, France.
(14)Fondation Fondamental, Créteil, France; Département de recherche clinique,
pôle universitaire 93G03, EPS Ville Evrard Neuilly sur Marne, Université
Sorbonne Paris-Nord, Neuilly-sur Marne, France.
(15)Fondation Fondamental, Créteil, France; Service Hospitalo-Universitaire de
Psychiatrie Générale et de Réhabilitation Psycho Sociale 29G01 et 29G02, CHRU de
Brest, Hôpital de Bohars, Brest, France.
(16)Fondation Fondamental, Créteil, France; Service de Psychiatrie et de
Psychologie Médicale, Centre Expert Dépression Résistante et Bipolaire
FondaMental, CHU de Toulouse, Hôpital Purpan, ToNIC Toulouse NeuroImaging
Centre, Toulouse, France; Université de Toulouse, INSERM, UPS, Toulouse, France.
(17)Fondation Fondamental, Créteil, France; Univ Franche-Comté, UMR INSERM 1322
LINC, Service de Psychiatrie de l’Adulte, CIC-1431 INSERM, CHU de Besançon,
France.
(18)Fondation Fondamental, Créteil, France; CHU Montpellier, Hôpital Lapeyronie,
Psychiatric Emergency and Post Emergency Department, Pole Urgence; IGF,
Université de Montpellier, CNRS, INSERM, Montpellier, France.
(19)Fondation Fondamental, Créteil, France; AP-HP, GH Saint-Louis – Lariboisière
– Fernand Widal, Pôle Neurosciences Tête et Cou, Département de Psychiatrie et
de Médecine Addictologique, INSERM UMRS 1144, Université Paris Cité, Paris,
France.
INTRODUCTION: Individuals with bipolar disorder (BD) frequently experience
comorbid medical conditions, with migraine being among the most common. While
research on migraine prevalence in BD is growing, the associated clinical
features, comorbidities, and treatments remain underexplored and sometimes
inconsistent. This study aimed to investigate the clinical features and
comorbidities associated with migraine in a large cohort of adults with BD.
METHODS: We assessed 4348 outpatients with BD attending FondaMental Advanced
Centers of Expertise. Sociodemographic and clinical data were collected using a
standardized procedure. Lifetime diagnoses for medical disorders, including
migraine, were based on self-reports, clinician assessments, and medical history
reviews. Multivariable logistic regression was used to assess associations
between migraine and sociodemographic factors, clinical characteristics,
comorbidities, and medications.
RESULTS: The prevalence of comorbid migraine in BD was 20 %, with 29.1 % in BD
type II and 19.9 % in BD type I. Multivariable analysis found that migraine was
associated with younger age (OR = 0.98, CI 95 % 0.97-0.99), females (OR = 2.15,
CI 95 % 1.56-2.95), sleep disturbances (OR = 1.06, CI 95 % 1.02-1.11), childhood
trauma (OR = 1.01, CI 95 % 1.00-1.02), hypertension (OR = 1.88, CI 95 %
1.13-3.15), psoriasis (OR = 1.61, CI 95 % 1.01-2.56), asthma (OR = 1.65, CI 95 %
1.02-2.67) and lower use of second-generation antipsychotics (OR = 0.65, CI 95 %
0.48-0.87).
CONCLUSION: Migraine is common in BD, especially in younger individuals,
females, and those with sleep disturbances or a history of trauma, who also
experience a higher clinical burden. These overlapping factors highlight the
need for an integrated treatment approach, addressing mood stabilization, sleep
management, and trauma support to reduce migraine burden in BD patients.
Copyright © 2025 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement: Declaration of competing interest The authors
declare the following financial interests/personal relationships which may be
considered as potential competing interests: Samalin reports a relationship with
Janssen-Cilag SAS that includes: board membership, consulting or advisory,
speaking and lecture fees, and travel reimbursement. Samalin reports a
relationship with Lundbeck SAS that includes: consulting or advisory, speaking
and lecture fees, and travel reimbursement. Samalin reports a relationship with
Otsuka that includes: consulting or advisory, speaking and lecture fees, and
travel reimbursement. Samalin reports a relationship with Rovi that includes:
consulting or advisory and travel reimbursement. Samalin reports a relationship
with Sanofi-Aventis France SA that includes: speaking and lecture fees. Samalin
reports a relationship with Teva that includes: consulting or advisory, speaking
and lecture fees, and travel reimbursement. Yrondi reports a relationship with
Janssen-Cilag SAS that includes: consulting or advisory, speaking and lecture
fees, and travel reimbursement. Yrondi reports a relationship with Lundbeck SAS
that includes: consulting or advisory, speaking and lecture fees, and travel
reimbursement. Yrondi reports a relationship with GW Research Ltd. that
includes: consulting or advisory, speaking and lecture fees, and travel
reimbursement. Yrondi reports a relationship with Camurus that includes:
consulting or advisory, speaking and lecture fees, and travel reimbursement.
Haffen reports a relationship with Johnson & Johnson that includes: consulting
or advisory, speaking and lecture fees, and travel reimbursement. Haffen reports
a relationship with Lundbeck SAS that includes: consulting or advisory, speaking
and lecture fees, and travel reimbursement. Haffen reports a relationship with
Neuraxpharm that includes: consulting or advisory, speaking and lecture fees,
and travel reimbursement. Haffen reports a relationship with Otsuka that
includes: consulting or advisory, speaking and lecture fees, and travel
reimbursement. Llorca reports a relationship with Eisai that includes:
consulting or advisory, speaking and lecture fees, and travel reimbursement.
Llorca reports a relationship with Ethypharm that includes: consulting or
advisory, speaking and lecture fees, and travel reimbursement. Llorca reports a
relationship with Janssen-Cilag SAS that includes: consulting or advisory,
speaking and lecture fees, and travel reimbursement. Llorca reports a
relationship with Lundbeck SAS that includes: consulting or advisory, speaking
and lecture fees, and travel reimbursement. Llorca reports a relationship with
MSD France SAS that includes: consulting or advisory, speaking and lecture fees,
and travel reimbursement. Llorca reports a relationship with Neuraxpharm that
includes: consulting or advisory, speaking and lecture fees, and travel
reimbursement. Llorca reports a relationship with Otsuka that includes:
consulting or advisory, speaking and lecture fees, and travel reimbursement.
Llorca reports a relationship with Rovi that includes: consulting or advisory,
speaking and lecture fees, and travel reimbursement. Llorca reports a
relationship with Sanofi-Aventis France SA that includes: consulting or
advisory, speaking and lecture fees, and travel reimbursement. If there are
other authors, they declare that they have no known competing financial
interests or personal relationships that could have appeared to influence the
work reported in this paper. The other authors have no conflicts of interest to
declare.